Keros Therapeutics Reports Q2 2026 Financial Results with $28.7M Net Loss

Keros Therapeutics, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $28.7 million, compared to a loss of $30.7 million in the same period of the previous year. For the six months ending June 30, 2026, the company recorded a net loss of $52.4 million, a stark contrast to a net income of $117.8 million for the first half of 2025, which was primarily driven by revenue from the Takeda Agreement. Total revenue for the second quarter of 2026 was zero, down from $18.2 million in the prior year, while revenue for the first half of 2026 was $0.4 million, significantly lower than $229.4 million in the same period of 2025.

Operating expenses for the second quarter of 2026 totaled $30.9 million, a decrease from $58.0 million in the prior year, largely due to reduced research and development costs, which fell to $22.3 million from $43.5 million. The decline in expenses was attributed to decreased spending on the elritercept program as activities transitioned to Takeda, as well as a reduction in personnel costs following a workforce reduction in 2025. General and administrative expenses also decreased to $8.6 million from $14.5 million, reflecting cost-cutting measures.

Keros Therapeutics has made strategic advancements, particularly in its clinical programs. The company is developing its lead product candidate, rinvatercept (KER-065), for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, with plans to announce initial data from a Phase 2 clinical trial in DMD in the first half of 2027. Additionally, the company is advancing elritercept (KER-050) for the treatment of cytopenias in patients with myelodysplastic syndromes and myelofibrosis, with a Phase 3 trial currently underway. In July 2026, Keros announced the dosing of the first patient in a Phase 3 trial for elritercept, triggering a $20 million milestone payment from Takeda.

As of June 30, 2026, Keros had cash and cash equivalents of $257.6 million, down from $287.4 million at the end of 2025. The company anticipates that its existing cash will be sufficient to fund operations into the first half of 2028. However, Keros continues to face challenges, including the need for additional funding to support ongoing clinical trials and operational costs. The company has indicated that it may need to raise capital through equity offerings or collaborations, as it does not currently have any products approved for sale and relies heavily on the success of its clinical candidates.

Looking ahead, Keros Therapeutics remains focused on advancing its clinical pipeline while managing its financial resources carefully. The company is aware of the potential impact of rising inflation and economic uncertainties on its operations and funding capabilities. Keros plans to continue its efforts in research and development, with the expectation of incurring operating losses in the near term as it works towards the commercialization of its product candidates.